BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe de nouveaux produits thérapeutiques pour le...
- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to...
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
4 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
12 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
26 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
52 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
156 | 9.36 | 92.4901185771 | 10.12 | 19.9 | 6.3 | 57015 | 12.32075892 | CS |
260 | 10.38 | 114.065934066 | 9.1 | 19.9 | 2.7 | 96823 | 8.59949892 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約